News und Analysen
![Veeva Data Cloud to Deliver New Approach for Patient and Prescriber Data](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Veeva Data Cloud to Deliver New Approach for Patient and Prescriber Data
Veeva Systems (NYSE: VEEV) today announced Veeva Data Cloud to help support the industry by bringing greater innovation and choice to the data market. Veeva Data Cloud will include longitudinal
![Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn
Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced that due to the unprecedented circumstances surrounding the COVID-19 pandemic, including associated delays in the regulatory
![Ipsen Provides Update on Palovarotene Clinical Programs](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Ipsen Provides Update on Palovarotene Clinical Programs
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) announced today it will begin to reinitiate palovarotene dosing in patients 14 years of age and older currently participating in its
![Quidel’s Lyra® SARS-CoV-2 Assay Receives Authorization for Expanded Use for Molecular Detection of COVID-19; Also Receives CE Mark, Health Canada Authorization](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Quidel’s Lyra® SARS-CoV-2 Assay Receives Authorization for Expanded Use for Molecular Detection of COVID-19; Also Receives CE Mark, Health Canada Authorization
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel’s Lyra®
![Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that in connection with the appointment of Jeff Ludwig as Puma’s Chief Commercial Officer, the Compensation Committee
![Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced it has entered
![IMV to Announce Fourth Quarter and Full Year 2019 Financial and Operational Results and Host Investor Conference Call and Webcast on March 31, 2020](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
IMV to Announce Fourth Quarter and Full Year 2019 Financial and Operational Results and Host Investor Conference Call and Webcast on March 31, 2020
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, announced today that it will hold a conference
![QIAGEN ernennt Thierry Bernard zum Chief Executive Officer](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
QIAGEN ernennt Thierry Bernard zum Chief Executive Officer
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Ernennung von Thierry Bernard zum Chief Executive Officer bekannt gegeben.
Zusätzlich hat eine gemeinsame Sitzung des
![QIAGEN Names Thierry Bernard as Chief Executive Officer](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
QIAGEN Names Thierry Bernard as Chief Executive Officer
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Thierry Bernard has been named Chief Executive Officer.
Additionally, a Joint Meeting of the Supervisory Board and the
![Novavax: Nicht Corona, sondern Influenza!](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Novavax: Nicht Corona, sondern Influenza!
Die Aktie des kleinen Biotechunternehmens Novavax (WKN: A2PKMZ) gehörte in den letzten Wochen schon zu den größten Gewinnern an der Börse (wir berichteten).
Grund hierfür war, dass Novavax sich auf
![Drägerwerk: Jetzt mischt Elon Musk mit!](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Drägerwerk: Jetzt mischt Elon Musk mit!
Drägerwerk (WKN: 555060) fertigt die in der Corona-Pandemie in Krankenhäusern so dringend benötigten Beatmungsgeräte. Dazu gab es jüngst einen Großauftrag von der Bundesregierung über 10.000 Geräte
![ADMA Biologics: NBCler feiern +127% mitten in der Krise](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
ADMA Biologics: NBCler feiern +127% mitten in der Krise
Erst letzte Woche konnten Mitglieder des No Brainer Clubs bei ADMA Biologics (WKN: A12FAG) die ersten +50% nach wenigen Stunden feiern und bereits am Freitag wurde unser offizielles Tradingziel von
![U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for EUCRISA® (crisaborole) ointment, 2%, extending
![QIAGEN Releases QIAstat-Dx Test Kit to the U.S. as First Syndromic Test for Detection of SARS-CoV-2 Coronavirus Under New FDA Policy](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
QIAGEN Releases QIAstat-Dx Test Kit to the U.S. as First Syndromic Test for Detection of SARS-CoV-2 Coronavirus Under New FDA Policy
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has begun shipments to the United States of its new QIAstat-Dx Respiratory SARS-CoV-2 Panel test to aid in diagnosing
![QIAGEN bietet ersten syndromischen QIAstat-Dx-Test zum Nachweis des Coronavirus SARS-CoV-2 in den USA unter neuen FDA Richtlinien an](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
QIAGEN bietet ersten syndromischen QIAstat-Dx-Test zum Nachweis des Coronavirus SARS-CoV-2 in den USA unter neuen FDA Richtlinien an
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute erste Lieferungen des neu entwickelten QIAstat-Dx-SARS-CoV-2-Atemwegspanel zur Diagnose von Patienten mit COVID-19-Infektion in die USA
![Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported
![MEDICREA Is Protected From the Consequences of the COVID-19 Pandemic](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
MEDICREA Is Protected From the Consequences of the COVID-19 Pandemic
The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED ; OTCQX Best Market –MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling
![German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany
Novocure (NASDAQ: NVCR) today announced that the German Federal Joint Committee, or G-BA, has updated its directive for Contracted Medical Care to include Tumor Treating Fields, establishing
![Gilead: Corona-Zulassung kein Kaufgrund – andere Aktie im Fokus!](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Gilead: Corona-Zulassung kein Kaufgrund – andere Aktie im Fokus!
Einige Anleger meinen derzeit, mit einer Aktie wie der von Gilead Sciences (WKN: 885823) die große Chance zu ergreifen, von der Corona-Krise zu profitieren. Hohe Kursgewinne lauern aber bei den
![Corona-Aktien kaufen: Heat Biologics ist Geschichte!](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Corona-Aktien kaufen: Heat Biologics ist Geschichte!
Anfang des Monats berichteten wir über den ausgebrochenen Corona-Hype rund um Heat Biologics (WKN: A2JB4Y). Die Firma wurde auch in der Folgezeit nicht müde, die Krise für sich zu nutzen.
Satte 5
![Navidea Biopharmaceuticals Announces Issuance of Patent Extension for Lymphoseek®](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Navidea Biopharmaceuticals Announces Issuance of Patent Extension for Lymphoseek®
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
![ADMA Biologics: Neue NBC-Granate mit +53% in wenigen Stunden!](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
ADMA Biologics: Neue NBC-Granate mit +53% in wenigen Stunden!
Aufmerksame Chat-Nutzer kannten die Aktie von ADMA Biologics (WKN: A12FAG) bereits. Der No Brainer Club nahm den Wert gestern in sein Portfolio auf und sprach eine Kaufempfehlung aus. Innerhalb
![Novocure Announces Optune Lua™ as the Brand Name for the NovoTTF-100L™ System](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Novocure Announces Optune Lua™ as the Brand Name for the NovoTTF-100L™ System
Novocure (NASDAQ: NVCR) announced today that Optune Lua is the brand name for the NovoTTF-100L System in malignant pleural mesothelioma (MPM). The U.S. Food and Drug Administration (FDA) previously
![Gilead: Chance auf Corona-Zulassung steigt!](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Gilead: Chance auf Corona-Zulassung steigt!
Der Corona-Krise zum Trotz klettert die Aktie des US-Pharmakonzerns Gilead Sciences (WKN: 885823) nahe Jahreshoch. Allein in den letzten zwei Handelstagen ging es für das Papier rund +15% nach oben.
![QIAGEN führt in Europa QIAstat-Dx-Testkit zur Erkennung des neuartigen Coronavirus SARS-CoV-2 nach erfolgter CE-Kennzeichnung ein](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
QIAGEN führt in Europa QIAstat-Dx-Testkit zur Erkennung des neuartigen Coronavirus SARS-CoV-2 nach erfolgter CE-Kennzeichnung ein
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass das neu entwickeltes QIAstat-Dx-SARS-CoV-2-Atemwegs-Panel die CE-Kennzeichnung für den Verkauf als In-vitro-Diagnosetest